Riding High-Throughput RNA Wave
Alithea Genomics, a Lausanne, Switzerland-based developer of multiplexed RNA sequencing kits, has raised CHF 6.9M ($8.8M) in seed funding, with the latest tranche led by Genku Ventures. The company's Mercurius™ kits enable extraction-free, high-throughput transcriptome profiling for drug screening and biomarker discovery. The capital will accelerate commercialization of 1536-well DRUG-seq kits and expand AI-ready datasets.
QIAGEN Acquisition Fuels RNA Momentum
The timing aligns with consolidation in transcriptomics: QIAGEN acquired Parse Biosciences for $225M in 2025 after Parse raised over $100M. 10x Genomics, with $1.3B+ in funding as a public company, expanded into clinical applications in January 2026. Alithea Genomics' extraction-free multiplexing—up to 384 samples per tube—targets cost barriers unmet by droplet-based systems like 10x Chromium.
Drug Screening Bottlenecks Persist
One-third of drug candidates fail Phase 1 due to undetected toxicity, costing pharma billions annually. Traditional RNA-seq requires labor-intensive extraction, limiting scale to dozens of samples per run. High-throughput screening demands thousands of profiles daily, but current kits cap at 96-plex with multi-day protocols. Extraction generates 40kg plastic waste per 1,000 samples, exacerbating pharma's 55% higher CO2 emissions per dollar than automotive.
Extraction-Free Kits Slash Costs
Mercurius DRUG-seq processes cells directly in 1536-well plates, detecting 13k-15k genes per well at under $1 per sample. Unlike Lexogen's 96-plex QuantSeq or QIAGEN's extraction-dependent QIAseq, Alithea's kits support full-length transcripts without custom primers. BRB-seq, invented by co-founder Daniel Alpern and published in Genome Biology (2019), underpins 384-plex bulk profiling cited in 40+ papers.
Full-Length Sensitivity Differentiates
FLASH-seq delivers ultra-sensitive single-cell RNA-seq, capturing 1.5-2x more genes than 10x Genomics' Chromium at lower cost per cell via plate-based indexing. Trusted by Bayer, Roche, and Syngenta, these kits reduce hands-on time by 95% and enable spheroid/organoid screening.
As Jan Van den Berghe, partner at Novalis Biotech, noted:
"Alithea’s technology has reached a level of scalability and data quality that fundamentally changes what is possible in transcriptomics."
Seed Extension Signals Scale-Up
Genku Ventures led the additional CHF 3M, bringing total seed to CHF 6.9M and reflecting conviction in Alithea's data engine for AI-driven discovery. Novalis Biotech doubled down, signaling strategic validation from life sciences specialists. This mission capital supports industrial-scale biology amid NGS reagent dominance by incumbents.
RNA-Seq Market Hits $10B
The global RNA sequencing market stands at $4.3B in 2024, projected to reach $10.3B by 2029 at 19.1% CAGR. Single-cell sequencing follows at $1.95B in 2025 to $3.46B by 2030. Trends favor multiplexing: Alithea's kits align with pharma's need for petabyte-scale data in drug discovery and crop science.
Incumbents Face Disruption Pressure
Lexogen offers undisclosed-funded pooling kits limited to 96-plex, while public giants like QIAGEN ($10B+ market cap) and 10x consolidate via acquisitions. Alithea's US subsidiary in Maryland complements Swiss HQ, positioning for global HTS adoption. ISO 9001 certification and OASIS Consortium partnership bolster tox screening credibility.
EPFL Inventors Drive Expertise
Co-founders hail from EPFL: Daniel Alpern invented BRB-seq, Riccardo Dainese developed microfluidics tools published in Nature Methods, and scientific advisor Bart Deplancke leads single-cell genomics. Chairman Frederik Decouttere scaled Genohm to Agilent acquisition in 2018. This repeat-exit team bridges academia to commercialization.
1536-Well Launch Accelerates
Funds target 1536-well DRUG-seq rollout unveiled at SLAS 2026, partnerships with Bayer and SPT Labtech, and AVITI24 sequencing upgrades. New CEO Frederik Decouttere eyes full-genome CRISPR screens and AI model training. US team expansions support service scaling to thousands of samples.